Related Experiment Video
Updated: Jan 26, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Splicing Factors Have an Essential Role in Prostate Cancer Progression and Androgen Receptor Signaling
1Department of Functional Biogerontology, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan. ktakayama-tky@umin.ac.jp.
Abstract:
Although inhibition of the androgen⁻androgen receptor (AR) axis effectively represses the growth of prostate cancer, most of all cases eventually become castration-resistant prostate cancers (CRPCs). Enhancement of the expression of AR and its variants along with the downstream signals is important for disease progression. AR-V7, a constitutive active form of AR, is generated as a result of RNA splicing. RNA splicing creates multiple transcript variants from one pre-messenger RNA (mRNA) by removing introns/exons to allow mRNA translation. The molecular mechanisms leading to marked increases of AR and generation of AR-V7 have been unclear. However, recent papers highlighted the roles of RNA splicing factors which promote AR expression and production of variants. Notably, a broad range of splicing components were aberrantly regulated in CRPC tissues. Interestingly, expression of various spliceosome genes is enhanced by RNA-binding protein splicing factor proline- and glutamine-rich (PSF/SFPQ), leading to changes in the expression of AR transcript variants. Moreover, inhibition of several splicing factors repressed tumor growth in vivo. Altered expression of splicing factors is correlated to biochemical recurrence in prostate cancer patients. Thus, these findings suggest that splicing factors would be a potential therapeutic target. This review focuses on the emerging roles of splicing factors in prostate cancer progression and AR signaling.
Insights
Splicing factors are key drivers in prostate cancer progression, promoting androgen receptor (AR) expression and variants like AR-V7. Targeting these splicing factors offers a promising therapeutic strategy for castration-resistant prostate cancer (CRPC).
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer growth is initially controlled by the androgen-androgen receptor (AR) axis.
- Most prostate cancers eventually develop resistance to castration, becoming castration-resistant prostate cancers (CRPCs).
- Increased AR expression and its variants, such as AR-V7, are crucial for CRPC progression.
Purpose of the Study:
- To explore the molecular mechanisms behind increased AR expression and AR-V7 generation in CRPC.
- To highlight the role of RNA splicing factors in prostate cancer progression and AR signaling.
- To identify splicing factors as potential therapeutic targets for CRPC.
Main Methods:
- Review of recent literature on RNA splicing factors and their impact on AR signaling.
- Analysis of aberrant regulation of splicing components in CRPC tissues.
- Investigation of the role of RNA-binding protein splicing factor proline- and glutamine-rich (PSF/SFPQ) in AR variant production.
- Evaluation of in vivo tumor growth inhibition by targeting splicing factors.
- Correlation analysis between splicing factor expression and biochemical recurrence in prostate cancer patients.
Main Results:
- RNA splicing factors significantly influence AR expression and the production of AR variants like AR-V7.
- Aberrant regulation of splicing components is observed in CRPC tissues.
- The splicing factor PSF/SFPQ enhances spliceosome gene expression, altering AR transcript variants.
- Inhibition of specific splicing factors demonstrated tumor growth repression in vivo.
- Altered splicing factor expression correlates with biochemical recurrence in prostate cancer patients.
Conclusions:
- Splicing factors play a critical role in the progression of prostate cancer, particularly in the development of CRPC.
- Targeting aberrant RNA splicing represents a novel and promising therapeutic strategy for prostate cancer.
- Splicing factors are potential therapeutic targets for managing advanced prostate cancer and overcoming castration resistance.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
RNA Splicing
Internal Receptors
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Signal Sequences and Sorting Receptors

